Matthew Troyer, MD
Principal Clinical Director at Denali Therapeutics
Location: San Francisco, California, United States
Matt Troyer, MD, is currently Principal Clinical Director at Denali Therapeutics, where he is responsible for Clinical Sciences and team leadership for the LRRK2 program. He is a neurologist with subspecialty training in Parkinsonís disease and movement disorders and more than 13 years of industry drug development experience. Dr. Troyer previously led programs at Medivation and at Merck, where he served as the neuroscience therapeutic area lead for Early Clinical Development. Before joining industry, Dr. Troyer completed a postdoctoral research fellowship in the laboratory of Robert Edwards at the University of California, San Francisco (UCSF). He then joined the neurology faculty at UCSF with both clinical and research responsibilities. Dr. Troyer received his medical degree from Stanford University, neurology residency training at the Harvard-Longwood Program, and fellowship training at the Institute of Neurology, Queen Square, London.